Pietro Di Lucia
Overview
Explore the profile of Pietro Di Lucia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andreata F, Laura C, Rava M, Krueger C, Ficht X, Kawashima K, et al.
Cell
. 2024 Jun;
187(15):4078-4094.e21.
PMID: 38897196
Reversing CD8 T cell dysfunction is crucial in treating chronic hepatitis B virus (HBV) infection, yet specific molecular targets remain unclear. Our study analyzed co-signaling receptors during hepatocellular priming and...
2.
Mooney A, Draper S, Burn O, Anderson R, Compton B, Tang C, et al.
JHEP Rep
. 2024 May;
6(5):101038.
PMID: 38694959
Background & Aims: Liver diseases resulting from chronic HBV infection are a significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of controlling the virus represent a...
3.
Fumagalli V, Rava M, Marotta D, Di Lucia P, Bono E, Giustini L, et al.
Nat Immunol
. 2024 Mar;
25(4):633-643.
PMID: 38486021
Vaccines have reduced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) morbidity and mortality, yet emerging variants challenge their effectiveness. The prevailing approach to updating vaccines targets the antibody response, operating...
4.
Andreata F, Moynihan K, Fumagalli V, Di Lucia P, Pappas D, Kawashima K, et al.
Sci Transl Med
. 2024 Jan;
16(729):eadi1572.
PMID: 38198572
CD8 T cells are key antiviral effectors against hepatitis B virus (HBV), yet their number and function can be compromised in chronic infections. Preclinical HBV models displaying CD8 T cell...
5.
Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, et al.
Vaccines (Basel)
. 2023 Oct;
11(10).
PMID: 37896949
The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the world population. To reach...
6.
Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, et al.
Res Sq
. 2023 Jun;
PMID: 37292970
The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the world population. To reach...
7.
Fumagalli V, Di Lucia P, Rava M, Marotta D, Bono E, Grassi S, et al.
EMBO Mol Med
. 2023 Mar;
15(5):e17580.
PMID: 36946379
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS-CoV-2 pandemic. Nirmatrelvir-an orally available inhibitor of the 3-chymotrypsin-like cysteine protease-has been shown to reduce the...
8.
Stoler-Barak L, Harris E, Peres A, Hezroni H, Kuka M, Di Lucia P, et al.
Nat Commun
. 2023 Mar;
14(1):1462.
PMID: 36927854
Protection from viral infections depends on immunoglobulin isotype switching, which endows antibodies with effector functions. Here, we find that the protein kinase DYRK1A is essential for B cell-mediated protection from...
9.
Ivanova Bencheva L, Donnici L, Ferrante L, Prandi A, Sinisi R, De Matteo M, et al.
Bioorg Med Chem Lett
. 2022 Jul;
73:128904.
PMID: 35868496
Chronic hepatitis B (CHB) is a major worldwide public health problem and novel anti-HBV therapies preventing liver disease progression to cirrhosis and hepatocellular carcinoma are urgently needed. Over the last...
10.
Fumagalli V, Venzin V, Di Lucia P, Moalli F, Ficht X, Ambrosi G, et al.
Sci Immunol
. 2022 Feb;
7(68):eabi6112.
PMID: 35213210
Group 1 innate lymphoid cells (ILCs), which comprise both natural killer (NK) cells and ILC1s, are important innate effectors that can also positively and negatively influence adaptive immune responses. The...